REG in COPD Marc Miravitlles Pneumology Department. Hospital Universitari Vall d’Hebron. Barcelona, Spain. (marcm@separ.es) Diagnosis of respiratory symptoms in general population Respondents 6,758 No respiratory symptoms 4,314 (64%) Respiratory symptoms 2,444 (36%) Did not consult physician 1,073 (44%) Consult physician 1,371 (56%) No spirometry 786 (57.4%) Spirometry 585 (42.6%) Miravitlles et al. Respir Med 2006; 100: 1973-1980 Knowledge of COPD % Survey in 6,758 subjects >40 years. Up to 24% reported having at least one chronic respiratory symptom 20 15 10 5 0 Non smokers Smokers High risk Miravitlles et al. Respir Med 2006; 100: 1973-1980 Spirometry in Primary Care Miravitlles et al. Arch Bronconeumol 2000; 36: 500-5 COPD-6 (FEV1/FEV6) Represas et al. Arch Bronconeumol 2010; 46: 426-432 Questionnaires and COPD Martinez et al. COPD 2008; 5: 85-95 Questionnaires and COPD Cut-off: 4 units Sensibility: 93.6% Specificity: 64.8% PPV: 69.5% NPV: 92.2% Classified: 78.1% Miravitlles et al. Med Clin 2012; 139: 522-530 Venn diagram of COPD The large rectangle represents the full study group. The clear circles represent the proportion of subjects with COPD (FEV1/FVC < 70%). Adults older than 50 years in New Zealand (n= 469) Marsh et al. Thorax 2008; 63: 761-767 (C) (D) 2 or more (B) 1 3 2 (A) 1 0 mMRC 0-1 CAT < 10 Respiratory Forum 2011 (Exacerbation history) 4 Risk (GOLD Classification of Airflow Limitation) Risk Combined assessment of COPD mMRC 2+ CAT 10+ Symptoms (mMRC or CAT score) J Vestbo Han et al. Lancet Infect Dis 2012; online Clasificación GOLD Han et al. Lancet Infect Dis 2012; online Clasificación GOLD Lange et al. AJRCCM 2012; 186: 975-981 Soriano et al. Chest 2012; online first Clasificación GOLD Mortalidad a los 10 años de seguimiento en pacientes GOLD D Soriano et al. Chest 2012; online first Clasificación GOLD Soriano et al. Chest 2012; online first Phenotype diagnosis Step 2 Phenotype characterisation Overlap COPD-asthma phenotype Exacerbator phenotype (2 or more ex/yr) (C) (D) (B) (A) No exacerbations < 2 ex/yr Emphysema phenotype Chronic bronchitis phenotype Miravitlles et al. Arch Bronconeumol 2012; 48: 247-257 Phenotypes of COPD AJRCCM 2010; 182: 598-604 Br J Gen Pract 2012: DOI:10.3399 Phenotypes of COPD Unpublished Phenotypes of COPD Unpublished Phenotype-guided treatment A No exacerbator B Overlap C Ex. with emphysema D Ex. with CB Bronchodilators ICS Muc/NAC Roflumilast Antibiotics Miravitlles et al. ERJ 2012; online Costs of COPD €/year 3000 2500 2000 1500 1000 500 0 Leve Moderada Grave Miravitlles et al. Chest 2003; 123: 784-791 Costs of COPD Visits and diagnostic tests 16 42 42 Hospital costs Drugs Miravitlles et al. Chest 2003; 123: 784-791 Costs of treatment of COPD Miravitlles et al. Respir Med 2009;103:714-721 Thorax 2013;68:4-6 BMJ 2012;345: e7390 SIDIAP Bolivar et al. Med Clin 2012; 138: 617-621 SIDIAP Bolivar et al. Med Clin 2012; 138: 617-621 REG in COPD • Diagnosis of COPD in Primary Care. • Validation of guidelines • Compliance with guidelines. • Cost of illness, cost-effectiveness • Validation of phenotypes • Safety of treatments.